Merrill Lynch reiterates New River as buy

New River Pharmaceuticals Inc. was reiterated a buy by Merrill Lynch analyst David Munno after New River's partner Shire announced that it has filed a lawsuit against Barr Pharmaceuticals and Impax Laboratories for infringement of its U.S. patent involving Adderall XR, which could lead to a longer delay for generic Adderall. Shares of the Radford, Va.-based specialty pharmaceutical company were down $0.81, or 1.63%, at $48.97 on volume of 46,953 shares versus the three-month running average of 90,934.9 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.